Yemarshet K. Gebreyohannes

A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutations

Erica N Evans, Alexandra K. Gardino, Joseph L. Kim et al. · Science Translational Medicine · 2017 · 209 citations

Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors

Yemarshet K. Gebreyohannes, Agnieszka Woźniak, Madalina-Elena Zhai et al. · Clinical Cancer Research · 2018 · 75 citations · Full text

Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification

Jasmien Cornillie, Agnieszka Woźniak, H. Li et al. · Clinical & Translational Oncology · 2019 · 57 citations

Mdm2-tp53 Inhibitor Bi-907828, Mdm2 Amplification, Oncology +8

Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing

Jasmien Cornillie, Agnieszka Woźniak, Haifu Li et al. · Molecular Cancer Therapeutics · 2019 · 38 citations · Full text

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different <i>KIT</i> Mutations

Yemarshet K. Gebreyohannes, Patrick Schöffski, Thomas Van Looy et al. · Molecular Cancer Therapeutics · 2016 · 31 citations · Full text

Pathology, Tumor Biology, Gastrointestinal Oncology +16